{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:07:25Z","timestamp":1791403645283,"version":"4.3.3"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2008,2,20]],"date-time":"2008-02-20T00:00:00Z","timestamp":1203465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2008,2,20]],"date-time":"2008-02-20T00:00:00Z","timestamp":1203465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychobiology"],"abstract":"<jats:p>The ability of chronic treatment with imipramine (an antidepressant with anti-panic activity) to antagonise the anxiogenic effects of 3 different compounds was investigated in the elevated plus-maze. The compounds chosen are likely to produce anxiety by activity at different sites in the central nervous system: yohimbine, by blocking the \u03b12-adrenoceptor; FG 7142, by action at the \u03b2-carboline site on the GABA-benzodiazepine receptor complex and pentylenetetrazole, by acting at the picrotoxinin site on this complex. Administration of imipramine following 21 days pre-treatment did not produce a significant consistent anxiolytic effect alone and was unable to reverse the anxiety produced by any of the 3 anxiogenic compounds. Our results are discussed in terms of the nature of the anxiety produced by the anxiogenic drugs and the sensitivity of tests of anxiety to anti-panic agents.<\/jats:p>","DOI":"10.1159\/000118363","type":"journal-article","created":{"date-parts":[[2008,2,20]],"date-time":"2008-02-20T06:10:26Z","timestamp":1203487826000},"page":"187-192","source":"Crossref","is-referenced-by-count":29,"title":["Chronic Treatment with Imipramine Does Not Reverse the Effects of 3 Anxiogenic Compounds in a Test of Anxiety in the Rat"],"prefix":"10.1159","author":[{"given":"Sandra E.","family":"File","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2008,2,20]]},"container-title":["Neuropsychobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/118363","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000118363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:46:10Z","timestamp":1777675570000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000118363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,20]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000118363","archive":["Portico"],"relation":{},"ISSN":["0302-282X","1423-0224"],"issn-type":[{"value":"0302-282X","type":"print"},{"value":"1423-0224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,20]]}}}